Skip to main content

Compare Stocks

Date Range: 

 Enanta PharmaceuticalsSyndax PharmaceuticalsPhibro Animal HealthG1 TherapeuticsRhythm Pharmaceuticals
SymbolNASDAQ:ENTANASDAQ:SNDXNASDAQ:PAHCNASDAQ:GTHXNASDAQ:RYTM
Price Information
Current Price$51.57$18.53$27.52$21.91$22.55
52 Week RangeHoldBuySellBuyBuy
MarketRank™
Overall Score1.41.81.61.51.8
Analysis Score3.13.40.53.53.4
Community Score2.32.52.22.42.6
Dividend Score0.00.02.50.00.0
Ownership Score1.72.51.71.72.5
Earnings & Valuation Score0.00.61.30.00.6
Analyst Ratings
Consensus RecommendationHoldBuySellBuyBuy
Consensus Price Target$65.29$27.82$22.00$54.40$50.67
% Upside from Price Target26.60% upside50.13% upside-20.06% downside148.29% upside124.69% upside
Trade Information
Market Cap$1.04 billion$894.05 million$1.11 billion$921.84 million$1.13 billion
Beta0.541.80.462.441.57
Average Volume141,425847,425138,7631,385,058440,553
Sales & Book Value
Annual Revenue$122.47 million$1.52 million$800.40 millionN/AN/A
Price / Sales8.50588.191.39N/AN/A
CashflowN/AN/A$2.48 per shareN/AN/A
Price / CashN/AN/A11.10N/AN/A
Book Value$22.70 per share$1.16 per share$4.65 per share$6.80 per share$6.40 per share
Price / Book2.2715.975.92N/AN/A
Profitability
Net Income$-36,170,000.00$-56,050,000.00$33.55 million$-122,450,000.00$-140,730,000.00
EPS($0.89)($1.84)$1.08($3.27)($3.86)
Trailing P/E RatioN/AN/A25.96N/AN/A
Forward P/E RatioN/AN/A24.35N/AN/A
P/E GrowthN/AN/A2.00N/AN/A
Net Margins-29.53%-4,656.63%5.37%N/AN/A
Return on Equity (ROE)-3.75%-77.47%23.70%-49.35%-55.21%
Return on Assets (ROA)-3.53%-52.27%5.99%-41.53%-50.73%
Dividend
Annual PayoutN/AN/A$0.48N/AN/A
Dividend YieldN/AN/A1.74%N/AN/A
Three-Year Dividend GrowthN/AN/A20.00%N/AN/A
Payout RatioN/AN/A44.44%N/AN/A
Years of Consecutive Dividend GrowthN/AN/A1 YearsN/AN/A
Debt
Debt-to-Equity RatioN/A0.15%1.97%0.10%N/A
Current Ratio18.08%11.71%2.88%7.45%13.24%
Quick Ratio18.08%11.71%1.61%7.45%13.25%
Ownership Information
Institutional Ownership Percentage90.78%83.78%50.32%77.89%88.43%
Insider Ownership Percentage10.93%9.50%50.05%14.49%9.49%
Miscellaneous
Employees141431,70012290
Shares Outstanding20.20 million48.25 million40.45 million42.07 million50.21 million
Next Earnings Date8/3/2021 (Estimated)8/5/2021 (Estimated)8/25/2021 (Estimated)8/4/2021 (Estimated)8/2/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $21.13Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up to $21.13
americanbankingnews.com - May 13 at 11:40 AM
Rhythm & Roots returning to Ninigret Park this Labor Day Weekend, tickets on sale on May 12Rhythm & Roots returning to Ninigret Park this Labor Day Weekend, tickets on sale on May 12
whatsupnewp.com - May 6 at 8:29 AM
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Reports First Quarter 2021 Financial ResultsRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
finanznachrichten.de - May 5 at 10:28 PM
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care ConferenceRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference
finanznachrichten.de - May 5 at 12:28 PM
Cardiac Rhythm Management (CRM) Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030Cardiac Rhythm Management (CRM) Devices And Equipment Global Market Report 2021: COVID 19 Impact and Recovery to 2030
ca.sports.yahoo.com - May 5 at 12:28 PM
Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care ConferenceRhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - May 5 at 12:28 PM
Cardiac Monitoring and Cardiac Rhythm ManagementCardiac Monitoring and Cardiac Rhythm Management
openpr.com - May 4 at 1:32 PM
Rhythm on the Rails to be as close to normal as possible this yearRhythm on the Rails to be 'as close to normal' as possible this year
swnewsmedia.com - May 4 at 1:32 PM
Rhythm Pharmaceuticals (NASDAQ:RYTM) Announces Quarterly  Earnings ResultsRhythm Pharmaceuticals (NASDAQ:RYTM) Announces Quarterly Earnings Results
americanbankingnews.com - May 4 at 7:46 AM
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass EstimatesRhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates
finance.yahoo.com - May 3 at 2:44 PM
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial ResultsRhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 3 at 9:43 AM
Global Cardiac Rhythm Management Devices Markets, 2016-2020 & 2021-2028Global Cardiac Rhythm Management Devices Markets, 2016-2020 & 2021-2028
prnewswire.com - April 30 at 7:02 PM
Global $29.9 Billion Cardiac Rhythm Management Devices Market to 2028Global $29.9 Billion Cardiac Rhythm Management Devices Market to 2028
ca.finance.yahoo.com - April 29 at 10:15 AM
Mullingar musician launches new single Rhythm of the MoonMullingar musician launches new single Rhythm of the Moon
westmeathexaminer.ie - April 27 at 2:30 PM
Global Cardiac Rhythm Management Devices Markets, 2021-2028 - Focus on Pacemaker, Defibrillators, CRT Devices - ResearchAndMarkets.comGlobal Cardiac Rhythm Management Devices Markets, 2021-2028 - Focus on Pacemaker, Defibrillators, CRT Devices - ResearchAndMarkets.com
ca.finance.yahoo.com - April 27 at 2:30 PM
Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2021 - 2028Cardiac Rhythm Management Devices Market Size, Share & Trends Analysis Report By Product, By Region And Segment Forecasts, 2021 - 2028
ca.sports.yahoo.com - April 27 at 8:38 AM
Scholarship winner announced at annual commemoration fo the Rhythm Night Club FireScholarship winner announced at annual commemoration fo the Rhythm Night Club Fire
natchezdemocrat.com - April 24 at 10:08 PM
Martin Scorsese and Irwin Winkler collaborating on musical feature ‘Fascinating Rhythm’Martin Scorsese and Irwin Winkler collaborating on musical feature ‘Fascinating Rhythm’
wionews.com - April 22 at 10:48 PM
Martin Scorsese, Irwin Winkler & John Carney Team For Musical ‘Fascinating Rhythm’ Inspired By Life & Music Of George GershwinMartin Scorsese, Irwin Winkler & John Carney Team For Musical ‘Fascinating Rhythm’ Inspired By Life & Music Of George Gershwin
deadline.com - April 22 at 5:47 PM
John Carney to Direct Musical ‘Fascinating Rhythm’ Inspired by Life of George GershwinJohn Carney to Direct Musical ‘Fascinating Rhythm’ Inspired by Life of George Gershwin
sg.news.yahoo.com - April 22 at 5:47 PM
Martin Scorsese, John Carney Team for George Gershwin-Inspired Musical Drama ‘Fascinating Rhythm’Martin Scorsese, John Carney Team for George Gershwin-Inspired Musical Drama ‘Fascinating Rhythm’
variety.com - April 22 at 5:47 PM
Dexorcist returns to Super Rhythm Trax with Miami Bass-inspired EPDexorcist returns to Super Rhythm Trax with Miami Bass-inspired EP
earmilk.com - April 21 at 4:41 PM
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 2.6%Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 2.6%
americanbankingnews.com - April 21 at 2:02 PM
Cardiac Rhythm Remote Monitoring Devices Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2027 | Future Market InsightsCardiac Rhythm Remote Monitoring Devices Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2027 | Future Market Insights
globalbankingandfinance.com - April 21 at 11:40 AM
Global Circadian Rhythm Sleep Disorder Market 2020 Sales Statistics, Data Analysis, Size Estimation and Application Assessment by 2026Global Circadian Rhythm Sleep Disorder Market 2020 Sales Statistics, Data Analysis, Size Estimation and Application Assessment by 2026
marketwatch.com - April 20 at 5:45 PM
DateCompanyBrokerageAction
2/9/2021Enanta PharmaceuticalsRoyal Bank of CanadaBoost Price Target
1/29/2021Enanta PharmaceuticalsJPMorgan Chase & Co.Upgrade
11/23/2020Enanta PharmaceuticalsEvercore ISIInitiated Coverage
10/26/2020Enanta PharmaceuticalsRoth CapitalBoost Price Target
9/23/2020Enanta PharmaceuticalsOppenheimerReiterated Rating
8/25/2020Enanta PharmaceuticalsPiper SandlerInitiated Coverage
7/27/2020Enanta PharmaceuticalsJMP SecuritiesUpgrade
3/17/2020Enanta PharmaceuticalsRobert W. BairdUpgrade
9/18/2019Enanta PharmaceuticalsBerenberg BankSet Price Target
5/24/2019Enanta PharmaceuticalsWolfe ResearchInitiated Coverage
8/8/2018Enanta PharmaceuticalsUBS GroupDowngrade
5/12/2021Syndax PharmaceuticalsMorgan StanleyLower Price Target
4/21/2021Syndax PharmaceuticalsB. RileyReiterated Rating
12/8/2020Syndax PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/8/2020Syndax PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/7/2020Syndax PharmaceuticalsBTIG ResearchBoost Price Target
12/7/2020Syndax PharmaceuticalsBarclaysBoost Price Target
12/2/2020Syndax PharmaceuticalsStifel NicolausInitiated Coverage
5/25/2020Syndax PharmaceuticalsNomuraReiterated Rating
5/22/2020Syndax PharmaceuticalsHC WainwrightDowngrade
5/8/2020Phibro Animal HealthCredit Suisse GroupLower Price Target
3/31/2020Phibro Animal HealthG.ResearchUpgrade
2/6/2020Phibro Animal HealthGabelliDowngrade
8/29/2019Phibro Animal HealthBank of AmericaLower Price Target
5/23/2019Phibro Animal HealthGuggenheimInitiated Coverage
4/9/2021G1 TherapeuticsNeedham & Company LLCReiterated Rating
11/17/2020G1 TherapeuticsRaymond JamesDowngrade
8/20/2020G1 TherapeuticsWedbushReiterated Rating
8/9/2020G1 TherapeuticsCowenReiterated Rating
1/27/2021Rhythm PharmaceuticalsCanaccord GenuityBoost Price Target
1/27/2021Rhythm PharmaceuticalsLADENBURG THALM/SH SHBoost Price Target
1/8/2020Rhythm PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.